What's happening
This bill requires annual reports from the commissioner of health on the cost increases of top state-funded prescription drugs and explanations from manufacturers.
Why it matters
Shines a spotlight on the most expensive and fastest-growing drug costs. By requiring annual lists of the top ten state-funded prescription drugs with the largest price hikes, the bill forces transparency around which drugs are driving public spending and how quickly their costs are rising.
Demands direct accountability from drug manufacturers. Pharmaceutical companies whose drugs make these lists must explain, in detail, the reasons for their price increases—including manufacturing, research, marketing, and profit data—potentially exposing questionable pricing practices.
Equips policymakers and the public with actionable data. The mandated breakdown of cost increases and state expenditures empowers lawmakers, advocates, and consumers to target cost-control efforts, negotiate better prices, or consider regulatory responses to excessive increases.
Could pressure industry behavior and inform broader reforms. Knowing that significant price hikes will be publicly reported and scrutinized may deter unjustified increases and provide a foundation for future legislation or interventions aimed at curbing drug costs.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Headline styles
Track Rising Drug Costs
Plain English, a few words. Used as the page title.
Sponsors
Senator · Senate District 23
No co-sponsors yet.
History
- Referred to health
Companion bill
The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.
Track Rising Drug Costs
In Assembly Committee · Health · Sponsor Sam Berger
Full text
2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
8587
IN SENATE
February 16, 2024
Introduced by Sen. SCARCELLA-SPANTON -- read twice and ordered printed, and when printed to be committed to the Committee on Health
AN ACT to amend the public health law, in relation to requiring the commissioner of health to include in annual reports information regarding the cost and increase in cost of certain prescription drugs
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. Subdivision 1 of section 277 of the public health law, as amended by section 18 of part A of chapter 56 of the laws of 2013, is amended to read as follows:
1. The commissioner, in consultation with the drug utilization review board, shall undertake periodic reviews, at least annually, of the preferred drug program which shall include consideration of:
(a) the volume of prior authorizations being handled, including data on the number and characteristics of prior authorization requests for particular prescription drugs;
(b) the quality of the program's responsiveness, including the quality of the administrator's responsiveness;
(c) complaints received from patients and providers;
(d) (i) a list of the ten prescription drugs on which the state expends the most money and for which the wholesale acquisition cost has increased by fifty percent or more over the past five years or by ten percent or more during the previous calendar year. The commissioner shall: include the percentage of the wholesale acquisition cost increase for each drug on the list; rank the drugs on the list from those with the largest increase in wholesale acquisition cost to those with the smallest increase; indicate whether each drug was included on the list based on its cost increase over the past five years or during the previous calendar year, or both; and provide the state's total expenditure for each drug on the list during the most recent calendar year; and
(ii) a list of the ten prescription drugs on which the state expends the most money and for which the cost to the state, net of rebates and other price concessions, has increased by fifty percent or more over the past five years or by ten percent or more during the previous calendar
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD06654-01-3
year. The commissioner shall rank the drugs on the list from those with the greatest increase in net cost to those with the smallest increase and indicate whether each drug was included on the list based on its cost increase over the past five years or during the previous calendar year, or both; and
(iii) a manufacturer of a prescription drug that appears on a list as described in subparagraph (i) or (ii) of this paragraph shall submit to the commissioner a report that explains: (A) all material factors that have contributed to the wholesale acquisition cost increase for such drug including but not limited to materials and manufacturing costs, spending on research and development costs, spending on marketing and advertising, and spending on patient assistance programs; (B) the percentage of the total wholesale acquisition cost increase attributable to each factor; (C) an explanation of the role of each factor in contributing to the wholesale acquisition cost increase; (D) the total revenue and the net profit of the manufacturer for the most recent calendar year; and (E) any additional information the manufacturer chooses to provide related to drug pricing decisions;
(e) the savings attributable to the state, and to each county and the city of New York, due to the provisions of this article;
[(e)] (f) the aggregate amount of supplemental rebates received in the previous fiscal year and in the current fiscal year, to date; and such amounts are to be broken out by fiscal year and by month;
[(f)] (g) the education and outreach program established by section two hundred seventy-six of this [article] title.
§ 2. This act shall take effect immediately.
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Sponsor's memo
Title of bill
An act to amend the public health law, in relation to requiring the commissioner of health to include in annual reports information regard- ing the cost and increase in cost of certain prescription drugs
Purpose
The purpose of this bill is to require manufacturers to report to the state how often the price of prescription drugs has increased and the rationale for such increases.
Summary of provisions
Section 1: amends subdivision 1 of section 277 of the public health law, as amended by section 18 of part A of chapter 56 of the laws of 2013 to require the commissioner and the drug utilization review board to provide a list of the ten prescription drugs on which the state spent the most money in the previous year, prescriptions that have increased more than 10% of the wholesale cost in the previous year, and drugs that have increased more than 50% over the previous five years. Manufacturers of prescription drugs that appear on these lists shall be required to provide a report explaining the rationale and factoring contributing to the cost increase.
Section 2: provides the effective date.
Justification
The exorbitant cost of prescription medications creates a barrier for patients to receive the treatments they need. Policymakers and the public would benefit from increased transparency, including requiring pharmaceutical companies to disclose the research, development, market- ing and manufacturing costs, as well as the profits, attributable to their drugs.
This legislation would require the state's Drug Utilization Review Board(DURB) to identify up to 10 prescription drugs on which the state spends significant health care dollars and for which the wholesale acquisition cost has increased by 50 percent or more over the last five years or increased by 10 percent or more over the last 12 months. The drug's manufacturer would be required to provide an explanation to the DURB on the pricing increase, including the factors contributing to the increase and the role each factor played in the increase. DURB would then issue an annual report based on the information it receives, but would be required to protect confidential commercial information and trade secrets.
Given the double-digit growth in the price of prescription drugs, trans- parency around the reasons for these increases would help in understand- ing the impact increase in drug prices has on the health care costs for employers and consumers and whether price increases are benefiting the public by funding research and development that improve patient care or are merely increasing the cost of health care.
Legislative history
New
Fiscal implications
None.
Effective date
This act shall take effect immediately.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.